← 產業報告目錄
Bevacizumab Injection Industry Research Report 2026
出版商 APO Research產業別 Healthcare & Life Sciences出版日期 2026-01-02頁數 121報告編號 APO-a624c55a71
授權報價
| Single User | $2,950 USD |
| Multi User | $4,430 USD |
| Enterprise | $5,900 USD |
報告摘要
The global Bevacizumab Injection market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Bevacizumab Injection is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Bevacizumab Injection is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
The Asia Pacific market for Bevacizumab Injection is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Bevacizumab Injection include Biocon, Cadila Pharmaceuticals, Centus, Dr Reddy's, Genentech, Hetero Group, Samsung Bioepis, Amgen and Bayer, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Bevacizumab Injection market in terms of revenue (US$ million) and, where applicable, sales volume (K Doses), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Doses) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Bevacizumab Injection Market by Company
Biocon
Cadila Pharmaceuticals
Centus
Dr Reddy's
Genentech
Hetero Group
Samsung Bioepis
Amgen
Bayer
Pfizer
Eli Lilly
Roche
Mylan
Bevacizumab Injection Segment by Type
100mg
400mg
Bevacizumab Injection Segment by Application
Age-related macular degeneration (AMD)
Ovarian Cancer
Others
Bevacizumab Injection Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Bevacizumab Injection market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Bevacizumab Injection and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Bevacizumab Injection.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Bevacizumab Injection manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Bevacizumab Injection by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Bevacizumab Injection in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
目錄 Table of Contents
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Bevacizumab Injection Market Size (2021-2032)
2.2.2 Global Bevacizumab Injection Sales (2021-2032)
2.2.3 Global Bevacizumab Injection Market Average Price (2021-2032)
2.3 Bevacizumab Injection by Type
2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
2.3.2 100mg
2.3.3 400mg
2.4 Bevacizumab Injection by Application
2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
2.4.2 Age-related macular degeneration (AMD)
2.4.3 Ovarian Cancer
2.4.4 Others
3 Market Competitive Landscape by Manufacturers
3.1 Global Bevacizumab Injection Market Competitive Situation by Manufacturers (2021 Versus 2025)
3.2 Global Bevacizumab Injection Sales (K Doses) of Manufacturers (2021-2026)
3.3 Global Bevacizumab Injection Revenue of Manufacturers (2021-2026)
3.4 Global Bevacizumab Injection Average Price by Manufacturers (2021-2026)
3.5 Global Bevacizumab Injection Industry Ranking, 2024 VS 2025 VS 2026
3.6 Global Manufacturers of Bevacizumab Injection, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Bevacizumab Injection, Product Type & Application
3.8 Global Manufacturers of Bevacizumab Injection, Established Date
3.9 Global Bevacizumab Injection Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Biocon
4.1.1 Biocon Company Information
4.1.2 Biocon Business Overview
4.1.3 Biocon Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.1.4 Biocon Bevacizumab Injection Product Portfolio
4.1.5 Biocon Recent Developments
4.2 Cadila Pharmaceuticals
4.2.1 Cadila Pharmaceuticals Company Information
4.2.2 Cadila Pharmaceuticals Business Overview
4.2.3 Cadila Pharmaceuticals Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.2.4 Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
4.2.5 Cadila Pharmaceuticals Recent Developments
4.3 Centus
4.3.1 Centus Company Information
4.3.2 Centus Business Overview
4.3.3 Centus Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.3.4 Centus Bevacizumab Injection Product Portfolio
4.3.5 Centus Recent Developments
4.4 Dr Reddy's
4.4.1 Dr Reddy's Company Information
4.4.2 Dr Reddy's Business Overview
4.4.3 Dr Reddy's Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.4.4 Dr Reddy's Bevacizumab Injection Product Portfolio
4.4.5 Dr Reddy's Recent Developments
4.5 Genentech
4.5.1 Genentech Company Information
4.5.2 Genentech Business Overview
4.5.3 Genentech Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.5.4 Genentech Bevacizumab Injection Product Portfolio
4.5.5 Genentech Recent Developments
4.6 Hetero Group
4.6.1 Hetero Group Company Information
4.6.2 Hetero Group Business Overview
4.6.3 Hetero Group Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.6.4 Hetero Group Bevacizumab Injection Product Portfolio
4.6.5 Hetero Group Recent Developments
4.7 Samsung Bioepis
4.7.1 Samsung Bioepis Company Information
4.7.2 Samsung Bioepis Business Overview
4.7.3 Samsung Bioepis Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.7.4 Samsung Bioepis Bevacizumab Injection Product Portfolio
4.7.5 Samsung Bioepis Recent Developments
4.8 Amgen
4.8.1 Amgen Company Information
4.8.2 Amgen Business Overview
4.8.3 Amgen Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.8.4 Amgen Bevacizumab Injection Product Portfolio
4.8.5 Amgen Recent Developments
4.9 Bayer
4.9.1 Bayer Company Information
4.9.2 Bayer Business Overview
4.9.3 Bayer Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.9.4 Bayer Bevacizumab Injection Product Portfolio
4.9.5 Bayer Recent Developments
4.10 Pfizer
4.10.1 Pfizer Company Information
4.10.2 Pfizer Business Overview
4.10.3 Pfizer Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.10.4 Pfizer Bevacizumab Injection Product Portfolio
4.10.5 Pfizer Recent Developments
4.11 Eli Lilly
4.11.1 Eli Lilly Company Information
4.11.2 Eli Lilly Business Overview
4.11.3 Eli Lilly Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.11.4 Eli Lilly Bevacizumab Injection Product Portfolio
4.11.5 Eli Lilly Recent Developments
4.12 Roche
4.12.1 Roche Company Information
4.12.2 Roche Business Overview
4.12.3 Roche Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.12.4 Roche Bevacizumab Injection Product Portfolio
4.12.5 Roche Recent Developments
4.13 Mylan
4.13.1 Mylan Company Information
4.13.2 Mylan Business Overview
4.13.3 Mylan Bevacizumab Injection Sales, Revenue and Gross Margin (2021-2026)
4.13.4 Mylan Bevacizumab Injection Product Portfolio
4.13.5 Mylan Recent Developments
5 Global Bevacizumab Injection Market Scenario by Region
5.1 Global Bevacizumab Injection Market Size by Region: 2021 VS 2025 VS 2032
5.2 Global Bevacizumab Injection Sales by Region: 2021-2032
5.2.1 Global Bevacizumab Injection Sales by Region: 2021-2026
5.2.2 Global Bevacizumab Injection Sales by Region: 2027-2032
5.3 Global Bevacizumab Injection Revenue by Region: 2021-2032
5.3.1 Global Bevacizumab Injection Revenue by Region: 2021-2026
5.3.2 Global Bevacizumab Injection Revenue by Region: 2027-2032
5.4 North America Bevacizumab Injection Market Facts & Figures by Country
5.4.1 North America Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032
5.4.2 North America Bevacizumab Injection Sales by Country (2021-2032)
5.4.3 North America Bevacizumab Injection Revenue by Country (2021-2032)
5.4.4 United States
5.4.5 Canada
5.5 Europe Bevacizumab Injection Market Facts & Figures by Country
5.5.1 Europe Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032
5.5.2 Europe Bevacizumab Injection Sales by Country (2021-2032)
5.5.3 Europe Bevacizumab Injection Revenue by Country (2021-2032)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Netherlands
5.6 Asia Pacific Bevacizumab Injection Market Facts & Figures by Country
5.6.1 Asia Pacific Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032
5.6.2 Asia Pacific Bevacizumab Injection Sales by Country (2021-2032)
5.6.3 Asia Pacific Bevacizumab Injection Revenue by Country (2021-2032)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 China Taiwan
5.6.10 Southeast Asia
5.7 South America Bevacizumab Injection Market Facts & Figures by Country
5.7.1 South America Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032
5.7.2 South America Bevacizumab Injection Sales by Country (2021-2032)
5.7.3 South America Bevacizumab Injection Revenue by Country (2021-2032)
5.7.4 Mexico
5.7.5 Brazil
5.7.6 Argentina
5.8 Middle East and Africa Bevacizumab Injection Market Facts & Figures by Country
5.8.1 Middle East and Africa Bevacizumab Injection Market Size by Country: 2021 VS 2025 VS 2032
5.8.2 Middle East and Africa Bevacizumab Injection Sales by Country (2021-2032)
5.8.3 Middle East and Africa Bevacizumab Injection Revenue by Country (2021-2032)
5.8.4 Turkey
5.8.5 Saudi Arabia
5.8.6 UAE
6 Segment by Type
6.1 Global Bevacizumab Injection Sales by Type (2021-2032)
6.1.1 Global Bevacizumab Injection Sales by Type (2021-2032) & (K Doses)
6.1.2 Global Bevacizumab Injection Sales Market Share by Type (2021-2032)
6.2 Global Bevacizumab Injection Revenue by Type (2021-2032)
6.2.1 Global Bevacizumab Injection Sales by Type (2021-2032) & (US$ Million)
6.2.2 Global Bevacizumab Injection Revenue Market Share by Type (2021-2032)
6.3 Global Bevacizumab Injection Price by Type (2021-2032)
7 Segment by Application
7.1 Global Bevacizumab Injection Sales by Application (2021-2032)
7.1.1 Global Bevacizumab Injection Sales by Application (2021-2032) & (K Doses)
7.1.2 Global Bevacizumab Injection Sales Market Share by Application (2021-2032)
7.2 Global Bevacizumab Injection Revenue by Application (2021-2032)
7.2.1 Global Bevacizumab Injection Sales by Application (2021-2032) & (US$ Million)
7.2.2 Global Bevacizumab Injection Revenue Market Share by Application (2021-2032)
7.3 Global Bevacizumab Injection Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Bevacizumab Injection Value Chain Analysis
8.1.1 Bevacizumab Injection Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Bevacizumab Injection Production Mode & Process
8.2 Bevacizumab Injection Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Bevacizumab Injection Distributors
8.2.3 Bevacizumab Injection Customers
9 Global Bevacizumab Injection Analyzing Market Dynamics
9.1 Bevacizumab Injection Industry Trends
9.2 Bevacizumab Injection Industry Drivers
9.3 Bevacizumab Injection Industry Opportunities and Challenges
9.4 Bevacizumab Injection Industry Restraints
10 Report Conclusion
11 Disclaimer
圖表清單 List of Tables & Figures
List of Tables
Table 1. Secondary Sources
Table 2. Primary Sources
Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million)
Table 5. Global Bevacizumab Injection Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
Table 6. Global Bevacizumab Injection Sales (K Doses) of Manufacturers (2021-2026)
Table 7. Global Bevacizumab Injection Sales Market Share by Manufacturers (2021-2026)
Table 8. Global Bevacizumab Injection Revenue of Manufacturers (2021-2026)
Table 9. Global Bevacizumab Injection Revenue Share by Manufacturers (2021-2026)
Table 10. Global Market Bevacizumab Injection Average Price (US$/Dose) of Manufacturers (2021-2026)
Table 11. Global Bevacizumab Injection Industry Ranking, 2024 VS 2025 VS 2026
Table 12. Global Manufacturers of Bevacizumab Injection, Manufacturing Sites & Headquarters
Table 13. Global Manufacturers of Bevacizumab Injection, Product Type & Application
Table 14. Global Bevacizumab Injection Manufacturers Established Date
Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 16. Global Bevacizumab Injection by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans)
Table 18. Biocon Company Information
Table 19. Biocon Business Overview
Table 20. Biocon Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 21. Biocon Bevacizumab Injection Product Portfolio
Table 22. Biocon Recent Developments
Table 23. Cadila Pharmaceuticals Company Information
Table 24. Cadila Pharmaceuticals Business Overview
Table 25. Cadila Pharmaceuticals Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 26. Cadila Pharmaceuticals Bevacizumab Injection Product Portfolio
Table 27. Cadila Pharmaceuticals Recent Developments
Table 28. Centus Company Information
Table 29. Centus Business Overview
Table 30. Centus Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 31. Centus Bevacizumab Injection Product Portfolio
Table 32. Centus Recent Developments
Table 33. Dr Reddy's Company Information
Table 34. Dr Reddy's Business Overview
Table 35. Dr Reddy's Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 36. Dr Reddy's Bevacizumab Injection Product Portfolio
Table 37. Dr Reddy's Recent Developments
Table 38. Genentech Company Information
Table 39. Genentech Business Overview
Table 40. Genentech Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 41. Genentech Bevacizumab Injection Product Portfolio
Table 42. Genentech Recent Developments
Table 43. Hetero Group Company Information
Table 44. Hetero Group Business Overview
Table 45. Hetero Group Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 46. Hetero Group Bevacizumab Injection Product Portfolio
Table 47. Hetero Group Recent Developments
Table 48. Samsung Bioepis Company Information
Table 49. Samsung Bioepis Business Overview
Table 50. Samsung Bioepis Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 51. Samsung Bioepis Bevacizumab Injection Product Portfolio
Table 52. Samsung Bioepis Recent Developments
Table 53. Amgen Company Information
Table 54. Amgen Business Overview
Table 55. Amgen Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 56. Amgen Bevacizumab Injection Product Portfolio
Table 57. Amgen Recent Developments
Table 58. Bayer Company Information
Table 59. Bayer Business Overview
Table 60. Bayer Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 61. Bayer Bevacizumab Injection Product Portfolio
Table 62. Bayer Recent Developments
Table 63. Pfizer Company Information
Table 64. Pfizer Business Overview
Table 65. Pfizer Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 66. Pfizer Bevacizumab Injection Product Portfolio
Table 67. Pfizer Recent Developments
Table 68. Eli Lilly Company Information
Table 69. Eli Lilly Business Overview
Table 70. Eli Lilly Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 71. Eli Lilly Bevacizumab Injection Product Portfolio
Table 72. Eli Lilly Recent Developments
Table 73. Roche Company Information
Table 74. Roche Business Overview
Table 75. Roche Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 76. Roche Bevacizumab Injection Product Portfolio
Table 77. Roche Recent Developments
Table 78. Mylan Company Information
Table 79. Mylan Business Overview
Table 80. Mylan Bevacizumab Injection Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2021-2026)
Table 81. Mylan Bevacizumab Injection Product Portfolio
Table 82. Mylan Recent Developments
Table 83. Global Bevacizumab Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Table 84. Global Bevacizumab Injection Sales by Region (2021-2026) & (K Doses)
Table 85. Global Bevacizumab Injection Sales Market Share by Region (2021-2026)
Table 86. Global Bevacizumab Injection Sales by Region (2027-2032) & (K Doses)
Table 87. Global Bevacizumab Injection Sales Market Share by Region (2027-2032)
Table 88. Global Bevacizumab Injection Revenue by Region (2021-2026) & (US$ Million)
Table 89. Global Bevacizumab Injection Revenue Market Share by Region (2021-2026)
Table 90. Global Bevacizumab Injection Revenue by Region (2027-2032) & (US$ Million)
Table 91. Global Bevacizumab Injection Revenue Market Share by Region (2027-2032)
Table 92. North America Bevacizumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 93. North America Bevacizumab Injection Sales by Country (2021-2026) & (K Doses)
Table 94. North America Bevacizumab Injection Sales by Country (2027-2032) & (K Doses)
Table 95. North America Bevacizumab Injection Revenue by Country (2021-2026) & (US$ Million)
Table 96. North America Bevacizumab Injection Revenue by Country (2027-2032) & (US$ Million)
Table 97. Europe Bevacizumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 98. Europe Bevacizumab Injection Sales by Country (2021-2026) & (K Doses)
Table 99. Europe Bevacizumab Injection Sales by Country (2027-2032) & (K Doses)
Table 100. Europe Bevacizumab Injection Revenue by Country (2021-2026) & (US$ Million)
Table 101. Europe Bevacizumab Injection Revenue by Country (2027-2032) & (US$ Million)
Table 102. Asia Pacific Bevacizumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 103. Asia Pacific Bevacizumab Injection Sales by Country (2021-2026) & (K Doses)
Table 104. Asia Pacific Bevacizumab Injection Sales by Country (2027-2032) & (K Doses)
Table 105. Asia Pacific Bevacizumab Injection Revenue by Country (2021-2026) & (US$ Million)
Table 106. Asia Pacific Bevacizumab Injection Revenue by Country (2027-2032) & (US$ Million)
Table 107. South America Bevacizumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 108. South America Bevacizumab Injection Sales by Country (2021-2026) & (K Doses)
Table 109. South America Bevacizumab Injection Sales by Country (2027-2032) & (K Doses)
Table 110. South America Bevacizumab Injection Revenue by Country (2021-2026) & (US$ Million)
Table 111. South America Bevacizumab Injection Revenue by Country (2027-2032) & (US$ Million)
Table 112. Middle East and Africa Bevacizumab Injection Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million)
Table 113. Middle East and Africa Bevacizumab Injection Sales by Country (2021-2026) & (K Doses)
Table 114. Middle East and Africa Bevacizumab Injection Sales by Country (2027-2032) & (K Doses)
Table 115. Middle East and Africa Bevacizumab Injection Revenue by Country (2021-2026) & (US$ Million)
Table 116. Middle East and Africa Bevacizumab Injection Revenue by Country (2027-2032) & (US$ Million)
Table 117. Global Bevacizumab Injection Sales by Type (2021-2026) & (K Doses)
Table 118. Global Bevacizumab Injection Sales by Type (2027-2032) & (K Doses)
Table 119. Global Bevacizumab Injection Sales Market Share by Type (2021-2026)
Table 120. Global Bevacizumab Injection Sales Market Share by Type (2027-2032)
Table 121. Global Bevacizumab Injection Revenue by Type (2021-2026) & (US$ Million)
Table 122. Global Bevacizumab Injection Revenue by Type (2027-2032) & (US$ Million)
Table 123. Global Bevacizumab Injection Revenue Market Share by Type (2021-2026)
Table 124. Global Bevacizumab Injection Revenue Market Share by Type (2027-2032)
Table 125. Global Bevacizumab Injection Price by Type (2021-2026) & (US$/Dose)
Table 126. Global Bevacizumab Injection Price by Type (2027-2032) & (US$/Dose)
Table 127. Global Bevacizumab Injection Sales by Application (2021-2026) & (K Doses)
Table 128. Global Bevacizumab Injection Sales by Application (2027-2032) & (K Doses)
Table 129. Global Bevacizumab Injection Sales Market Share by Application (2021-2026)
Table 130. Global Bevacizumab Injection Sales Market Share by Application (2027-2032)
Table 131. Global Bevacizumab Injection Revenue by Application (2021-2026) & (US$ Million)
Table 132. Global Bevacizumab Injection Revenue by Application (2027-2032) & (US$ Million)
Table 133. Global Bevacizumab Injection Revenue Market Share by Application (2021-2026)
Table 134. Global Bevacizumab Injection Revenue Market Share by Application (2027-2032)
Table 135. Global Bevacizumab Injection Price by Application (2021-2026) & (US$/Dose)
Table 136. Global Bevacizumab Injection Price by Application (2027-2032) & (US$/Dose)
Table 137. Key Raw Materials
Table 138. Raw Materials Key Suppliers
Table 139. Bevacizumab Injection Distributors List
Table 140. Bevacizumab Injection Customers List
Table 141. Bevacizumab Injection Industry Trends
Table 142. Bevacizumab Injection Industry Drivers
Table 143. Bevacizumab Injection Industry Restraints
Table 144. Authors List of This Report
List of Figures
Figure 1. Research Methodology
Figure 2. Research Process
Figure 3. Key Executives Interviewed
Figure 4. Bevacizumab Injection Product Image
Figure 5. Global Bevacizumab Injection Revenue (US$ Million), 2021 VS 2025 VS 2032
Figure 6. Global Bevacizumab Injection Market Size (2021-2032) & (US$ Million)
Figure 7. Global Bevacizumab Injection Sales (2021-2032) & (K Doses)
Figure 8. Global Bevacizumab Injection Average Price (US$/Dose) & (2021-2032)
Figure 9. 100mg Product Image
Figure 10. 400mg Product Image
Figure 11. Age-related macular degeneration (AMD) Product Image
Figure 12. Ovarian Cancer Product Image
Figure 13. Others Product Image
Figure 14. Global Bevacizumab Injection Revenue Share by Manufacturers in 2025
Figure 15. Global Manufacturers of Bevacizumab Injection, Manufacturing Sites & Headquarters
Figure 16. Global Top 5 and 10 Bevacizumab Injection Players Market Share by Revenue in 2025
Figure 17. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
Figure 18. Global Bevacizumab Injection Market Size by Region (US$ Million): 2021 VS 2025 VS 2032
Figure 19. Global Bevacizumab Injection Sales by Region in 2025
Figure 20. Global Bevacizumab Injection Revenue by Region in 2025
Figure 21. North America Bevacizumab Injection Market Size by Country in 2025
Figure 22. North America Bevacizumab Injection Sales Market Share by Country (2021-2032)
Figure 23. North America Bevacizumab Injection Revenue Market Share by Country (2021-2032)
Figure 24. United States Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 25. Canada Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 26. Europe Bevacizumab Injection Market Size by Country in 2025
Figure 27. Europe Bevacizumab Injection Sales Market Share by Country (2021-2032)
Figure 28. Europe Bevacizumab Injection Revenue Market Share by Country (2021-2032)
Figure 29. Germany Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 30. France Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 31. U.K. Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 32. Italy Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 33. Netherlands Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 34. Asia Pacific Bevacizumab Injection Market Size by Country in 2025
Figure 35. Asia Pacific Bevacizumab Injection Sales Market Share by Country (2021-2032)
Figure 36. Asia Pacific Bevacizumab Injection Revenue Market Share by Country (2021-2032)
Figure 37. China Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 38. Japan Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 39. South Korea Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 40. India Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 41. Australia Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 42. China Taiwan Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 43. Southeast Asia Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 44. Southeast Asia Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 45. South America Bevacizumab Injection Market Size by Country in 2025
Figure 46. South America Bevacizumab Injection Sales Market Share by Country (2021-2032)
Figure 47. South America Bevacizumab Injection Revenue Market Share by Country (2021-2032)
Figure 48. Mexico Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 49. Brazil Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 50. Argentina Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 51. Middle East and Africa Bevacizumab Injection Market Size by Country in 2025
Figure 52. Middle East and Africa Bevacizumab Injection Sales Market Share by Country (2021-2032)
Figure 53. Middle East and Africa Bevacizumab Injection Revenue Market Share by Country (2021-2032)
Figure 54. Turkey Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 55. Saudi Arabia Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 56. UAE Bevacizumab Injection Revenue Growth Rate (2021-2032) & (US$ Million)
Figure 57. Global Bevacizumab Injection Sales Market Share by Type (2021-2032)
Figure 58. Global Bevacizumab Injection Revenue Market Share by Type (2021-2032)
Figure 59. Global Bevacizumab Injection Price (US$/Dose) by Type (2021-2032)
Figure 60. Global Bevacizumab Injection Sales Market Share by Application (2021-2032)
Figure 61. Global Bevacizumab Injection Revenue Market Share by Application (2021-2032)
Figure 62. Global Bevacizumab Injection Price (US$/Dose) by Application (2021-2032)
Figure 63. Bevacizumab Injection Value Chain
Figure 64. Bevacizumab Injection Production Mode & Process
Figure 65. Direct Comparison with Distribution Share
Figure 66. Distributors Profiles
Figure 67. Bevacizumab Injection Industry Opportunities and Challenges
提及公司
BioconCadila PharmaceuticalsCentusDr Reddy'sGenentechHetero GroupSamsung BioepisAmgenBayerPfizerEli LillyRocheMylan
量子訊息有限公司為 APO Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們